The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2017

Filed:

Mar. 14, 2014
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;

Universite Paris Descartes, Paris, FR;

Universite Pierre ET Marie Curie—upmc, Paris, FR;

Assistance Publique—hopitaux DE Paris (Aphp), Paris, FR;

Inventors:

Ziad Mallat, Paris, FR;

Alain Tedgui, Paris, FR;

Tabassome Simon, Paris, FR;

Nicolas Danchin, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); C07K 16/2875 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6872 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 14/525 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 33/53 (2013.01); G01N 2333/70575 (2013.01); G01N 2800/324 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.


Find Patent Forward Citations

Loading…